The downgrade by a major financial institution like Barclays, accompanied by a drastic reduction in the price target, is likely to negatively impact investor sentiment and the stock price of RAPT Therapeutics in the short term. Such a significant adjustment suggests a change in the company's valuation and future earnings potential as perceived by the analyst.